RUGHETTI, Aurelia
 Distribuzione geografica
Continente #
NA - Nord America 3.439
EU - Europa 1.601
AS - Asia 527
AF - Africa 65
SA - Sud America 46
OC - Oceania 2
Totale 5.680
Nazione #
US - Stati Uniti d'America 3.414
IT - Italia 812
SE - Svezia 273
IN - India 228
UA - Ucraina 159
CN - Cina 139
FI - Finlandia 137
SG - Singapore 108
DE - Germania 63
AR - Argentina 41
GB - Regno Unito 32
EG - Egitto 31
BG - Bulgaria 27
IE - Irlanda 25
TG - Togo 25
CA - Canada 21
FR - Francia 20
HK - Hong Kong 19
CH - Svizzera 14
IR - Iran 13
BE - Belgio 9
KR - Corea 8
RO - Romania 8
ZA - Sudafrica 7
PL - Polonia 5
MX - Messico 4
TW - Taiwan 4
AT - Austria 3
CO - Colombia 3
DK - Danimarca 3
AU - Australia 2
BR - Brasile 2
KZ - Kazakistan 2
MA - Marocco 2
MK - Macedonia 2
NL - Olanda 2
NO - Norvegia 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
ES - Italia 1
GR - Grecia 1
JP - Giappone 1
KH - Cambogia 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
Totale 5.680
Città #
Fairfield 511
Rome 435
Chandler 315
Woodbridge 250
Ashburn 242
Seattle 202
Cambridge 180
Houston 178
Wilmington 161
Ann Arbor 150
New York 111
Princeton 106
Plano 82
Beijing 76
San Paolo di Civitate 62
Jacksonville 61
Helsinki 53
Boston 52
Lawrence 52
Millbury 39
Milan 38
Singapore 36
San Diego 35
Dearborn 32
Damanhur 29
Federal 29
Sofia 27
Andover 26
Boardman 25
Dublin 25
Lomé 25
Des Moines 21
Hong Kong 19
Norwalk 18
Falls Church 17
Fremont 15
Toronto 14
Bremen 13
Indore 11
Lappeenranta 10
Brussels 9
Phoenix 8
Salt Lake City 8
Shanghai 8
Turin 8
Hefei 6
Leawood 6
London 6
Los Angeles 6
Putignano 6
Casatenovo 5
Diano d'Alba 5
Florence 5
Grafing 5
Kunming 5
Palermo 5
Pomezia 5
Redwood City 5
San Isidro 5
San Mateo 5
Bühl 4
Ercolano 4
Livorno 4
Mexico City 4
Muizenberg 4
Naples 4
Pune 4
Renens 4
Zanjan 4
Auburn Hills 3
Avellino 3
Bengaluru 3
Birmingham 3
Chiesina Uzzanese 3
Dongjak-gu 3
Fuzhou 3
Germiston 3
Guangzhou 3
Gunzenhausen 3
Kilburn 3
Lucknow 3
Mannheim 3
Modena 3
Monte Grande 3
Nanchang 3
Nanjing 3
Ottawa 3
Portici 3
Sacramento 3
Somerville 3
Taipei 3
Vaas 3
Velletri 3
Wroclaw 3
Zhengzhou 3
Anguillara 2
Arzano 2
Bagnacavallo 2
Baotou 2
Bologna 2
Totale 4.028
Nome #
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway 149
Circulating CD137 + T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients 135
The macrophage Galactose-type C-type Lectin (MGL) modulates regulatory T cell functions 134
Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets 118
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial 110
Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response 104
Anisakis pegreffii impacts differentiation and function of human dendritic cells 98
Tumor Associated Tn-MUC1 Glycoform is Internalized through the Macrophage Galactose-type C-type Lectin and delivered to the HLA Class I and II Compartments in Dendritic Cells. 96
MGL receptor and immunity: when the ligand can make the difference 90
The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer. A meta-analysis 88
Tumor-derived microvesicles modulate antigen cross-processing via reactive oxygen species-mediated alkalinization of phagosomal compartment in dendritic cells 86
Immune effects of trastuzumab. 83
Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-Expressing Cells 83
null 83
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response 81
Past, present and future strategies of immunotherapy in gynecological malignancies 79
Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. 77
The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells 76
Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells 75
Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region 75
Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer 74
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines 74
Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors 73
Characterization of monoclonal antibody 436 recognizing the ARG-PRO-ALA-PRO sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells 72
Gene expression profiles of antigenic proteins of third stage larvae of the zoonotic nematode Anisakis pegreffii in response to temperature conditions 72
Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. 71
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 70
Multiple Tumor Associated Peptide Vaccination As Consolidation Treatment In Women Affected by Breast and Ovarian Cancer 69
Funzione immunoregolatoria dell'antigene tumore associato MUC1 durante l'ematopoiesi 66
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study 66
Human decay accelerating factor transgenic pigs for xenotransplantation obtained by sperm-mediated gene transfer 66
Anticorpi monoclonali contro la lipasi da Candida rugosa 65
A comparative analysis of serum and serum-free media for generation of clinical grade DCs 65
The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. 64
Multicentre harmonisation of a six-colour flow cytometry panel for naïve/memory T cell immunomonitoring 63
Immunohistochemical characterization of immune infiltrate in tumor microenvironment of glioblastoma 63
Distinct pathways of antigen processing of MUC1 tumor-associated glycoprotein in dendritic cells (DCs) 62
Recombinant tumor associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. 62
Clinical and Developmental Immunology 62
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 61
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach 60
bcl-2 overexpression inhibites apoptosis and promotes the phenotype and morphological differentiation of human mammary epithelial cells 60
null 60
RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients 57
Monoclonal antibodies in gynecological cancer: a critical point of view. 55
Regulated expression of MUC1 epithelial antigen in erythropoiesis 55
Immune response to the polymorphic epithelial mucin (PEM) 54
Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients 53
Monoclonal antibodies against Candida rugosa lipase 53
MGL lectin receptor and immunosuppression networks in glioblastoma 52
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137 + T-cells 52
Immunohistochemical analysis of the distribution of a breast tumor associated antigen recognized by a monoclonal antibody 52
Circulating CD137+T cells as an immune biomarker for response to anti-PD1 immunotherapy in NSCLC patients 48
Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice 46
Combining anti-tumor immunotherapy and tumor ablation techiniques: immunological and biological basis. 46
Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation 46
T cell activation induced by MUC1 synthetic glycopeptides 45
Seasonal modulation of the C-type lectin MGL on human DCs 45
Transfected human dendritic cells to induce antitumor immunity 45
null 45
Antimicrobial lipase antibody their nucleotide and aminoacid sequences and uses thereof 43
Enhancement of Candida rugosa lipase activity by immunoglobulin light chain 42
HER2-based recombinant immunogen to target DCs through Fc gamma Rs for cancer immunotherapy 41
Investigating patterns of immune interaction in ovarian cancer: probing the O-glycoproteome by the macrophage galactose-like C-type Lectin (MGL) 41
IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells 41
Human B-cell immune response to the polymorphic epithelial mucin. 40
Immunoglobulin light chain increases enzymatic activity of Candida rugosa lipase. 40
ANTIMICROBIAL LIPASE ANTIBODIES THEIR NUCLEOTIDE AND AMINOACID SEQUENCES AND USES THEREOF”. 40
Macrophage galactose-like lectin mediated interactions: investigating immunosuppressive mechanisms in glioblastoma 39
Effects of G-CSF and GM-CSF administration on T cell proliferation and phagocyte cell surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation 39
Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma 39
MUC1 expression in non lymphoid differential cell lineages from CD34+ cells 38
Isolation of MUC-1 primed B lymphocytes from tumour draining lymph nodes using immunomagnetic beads. 38
Generation and characterisation of monoclonal antibodies against lipases from Candida rugosa 38
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients 38
Engagement of MGL by the Tn-tumor glycoform of MUC1 induces DC signaling and activation 37
Exosomes factory: a new strategy for antitumour vaccines 37
Exosome factory: a new strategy for antitumor vaccines. 36
DCs internalize and efficiently process Tn-MUC1 glycoprotein through MGL. 36
Polymeric nanoparticles decorated with monoclonal antibodies: a new immobilization strategy for increasing lipase activity 36
In normal aging ventricular system never attains pathological values of Evans' index 36
Enhancement of Candida rugosa lipase activity by immunoglobulin light chain 35
hDAF TRANSGENIC PIG GENERATION: A NEW SOURCE OF ORGANS FOR XENOTRANSPLANTATION 35
Breaking tolerance against MUC1 self antigen: implication for immunotherapy 34
MAGE-A and NY-ESO-1 expression in cervical cancer: investigation on prognostic factors and effect of chemotherapy 33
Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance 31
Effects on the immune response following tumor ablation by radiofrequency. 31
MUC1 cross talk molecule during erythroid differentiation. 31
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors 30
Immunomodulatory effects of radiofrequency tumor ablation in liver tumor patients. 30
Immunoregulatory function of MUC1 tumor antigen during hematopoiesis 30
Recombinant tumor associated MUC1 impairs differentiation and function of Dendritic Cells 29
Dendritic cells for MUC1-based cancer immunotherapy 29
Exosome factory: new strategy for the production of cell-free anti-tumor vaccine. 29
Exosome factory: new strategy for the production of cell-free antitumor vaccines 29
Tumour associated MUC1 glycoform interacts with dendritic cells through Mgl 27
Human B cell immune response to selected epitopes of the polimorphic Epithelial Mucin (PEM) in cancer patients 27
Soluble Immune checkpoints, gut metabolites and performance status as parameters of response to Nivolumab treatment in NSCLC patients 27
Immunomodulatory function of tumor antigen carrying vesiscles. 26
Valutazione della immunogenicità di epitopi tumore associati della glicoproteina MUC1 25
Totale 5.672
Categoria #
all - tutte 16.557
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 251
selected - selezionate 0
volume - volumi 0
Totale 16.808


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019298 0 0 0 0 0 0 0 0 0 0 169 129
2019/20201.059 145 31 22 48 102 124 139 126 101 126 64 31
2020/2021539 52 49 34 44 44 40 12 42 50 113 45 14
2021/20221.164 30 58 86 41 144 32 31 100 92 85 264 201
2022/20231.322 234 245 79 129 136 139 28 100 85 35 55 57
2023/20241.018 46 119 53 63 124 246 45 102 15 120 85 0
Totale 5.994